DE69427332D1 - Galanthamin-Derivat, ein Verfahren zu seiner Herstellung und seine Verwendung als Medikament - Google Patents

Galanthamin-Derivat, ein Verfahren zu seiner Herstellung und seine Verwendung als Medikament

Info

Publication number
DE69427332D1
DE69427332D1 DE69427332T DE69427332T DE69427332D1 DE 69427332 D1 DE69427332 D1 DE 69427332D1 DE 69427332 T DE69427332 T DE 69427332T DE 69427332 T DE69427332 T DE 69427332T DE 69427332 D1 DE69427332 D1 DE 69427332D1
Authority
DE
Germany
Prior art keywords
medicament
preparation
alkylaminocarbonyloxy
galanthamine derivative
alkylaminocarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69427332T
Other languages
English (en)
Other versions
DE69427332T2 (de
Inventor
Kosley, Jr
Larry Davis
Veronica Taberna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of DE69427332D1 publication Critical patent/DE69427332D1/de
Application granted granted Critical
Publication of DE69427332T2 publication Critical patent/DE69427332T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69427332T 1993-10-15 1994-10-10 Galanthamin-Derivat, ein Verfahren zu seiner Herstellung und seine Verwendung als Medikament Expired - Lifetime DE69427332T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/137,443 US6323196B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (2)

Publication Number Publication Date
DE69427332D1 true DE69427332D1 (de) 2001-07-05
DE69427332T2 DE69427332T2 (de) 2001-10-11

Family

ID=22477457

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69427332T Expired - Lifetime DE69427332T2 (de) 1993-10-15 1994-10-10 Galanthamin-Derivat, ein Verfahren zu seiner Herstellung und seine Verwendung als Medikament

Country Status (24)

Country Link
US (1) US6323196B1 (de)
EP (2) EP0648771B1 (de)
JP (1) JP2718637B2 (de)
KR (1) KR100189043B1 (de)
CN (1) CN1039011C (de)
AT (1) ATE201687T1 (de)
AU (1) AU679560B2 (de)
CA (1) CA2118171C (de)
CZ (1) CZ283561B6 (de)
DE (1) DE69427332T2 (de)
DK (1) DK0648771T3 (de)
EG (1) EG20747A (de)
ES (1) ES2158876T3 (de)
FI (1) FI108724B (de)
GR (1) GR3036068T3 (de)
IL (1) IL111273A (de)
NO (1) NO307463B1 (de)
NZ (1) NZ264681A (de)
PL (1) PL177754B1 (de)
PT (1) PT648771E (de)
RO (1) RO114132B1 (de)
RU (1) RU2113438C1 (de)
TW (1) TW375615B (de)
ZA (1) ZA948060B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP1133230A4 (de) * 1998-11-23 2004-05-26 Bonnie M Davis Dosisformulierungen für acetylcholinesterase-inhibitoren
DE69912311T2 (de) 1998-12-24 2004-07-29 Janssen Pharmaceutica N.V. Galantamin-zusammensetzung mit gesteuerter freisetzung
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
PL202463B1 (pl) 2000-03-31 2009-06-30 Sanochemia Pharmazeutika Ag Pochodne galantaminy, sposób ich wytwarzania, środek leczniczy zawierajacy te pochodne, zastosowanie pochodnej galantaminy do wytwarzania środków leczniczych, sposób wytwarzania środków leczniczych oraz sposób oddzielania (+)- i (-)-izomerów
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20040142970A1 (en) * 2002-11-01 2004-07-22 Kathryn Chung Treatment of hyperkinetic movement disorder with donepezil
US20050048543A1 (en) * 2003-07-11 2005-03-03 Jeroen Aerssens CHRNA2 genetic markers associated with galantamine response
WO2005042762A2 (en) * 2003-10-28 2005-05-12 Genaissance Pharmaceuticals, Inc. Lrpap1 genetic markers associated with galantamine response
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US7250258B2 (en) * 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
EP1895995A2 (de) * 2005-05-13 2008-03-12 Alza Corporation Mehrschichtige transdermale systeme zur galantamine abgabe
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP1777222A1 (de) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinesterase Inhibitoren mit erhöter Blut Hirn Schranke Permeabilität zur Behandlung von kognitiven Störungen
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
KR100786371B1 (ko) * 2006-12-07 2007-12-17 한국화학연구원 갈란타민의 제조방법
DK2137192T3 (da) 2008-04-14 2014-05-26 Neurodyn Life Sciences Inc Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme
AU2010275431A1 (en) * 2009-07-23 2012-02-23 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
ATE411026T1 (de) * 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
ATE183084T1 (de) 1991-05-14 1999-08-15 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
KR100189043B1 (ko) 1999-06-01
ZA948060B (en) 1995-06-09
EP1020469A2 (de) 2000-07-19
AU679560B2 (en) 1997-07-03
ES2158876T3 (es) 2001-09-16
US6323196B1 (en) 2001-11-27
KR950011444A (ko) 1995-05-15
NO943894L (no) 1995-04-18
ATE201687T1 (de) 2001-06-15
EP0648771A1 (de) 1995-04-19
PL305455A1 (en) 1995-04-18
NO307463B1 (no) 2000-04-10
DK0648771T3 (da) 2001-08-27
DE69427332T2 (de) 2001-10-11
IL111273A (en) 1998-04-05
NZ264681A (en) 1997-12-19
FI944822A0 (fi) 1994-10-13
AU7581294A (en) 1995-05-04
CA2118171C (en) 1999-12-28
CZ254794A3 (en) 1995-05-17
JPH07188238A (ja) 1995-07-25
FI944822A (fi) 1995-04-16
CA2118171A1 (en) 1995-04-16
EP1020469A3 (de) 2000-07-26
PL177754B1 (pl) 2000-01-31
RU2113438C1 (ru) 1998-06-20
FI108724B (fi) 2002-03-15
EP0648771B1 (de) 2001-05-30
NO943894D0 (no) 1994-10-14
EG20747A (en) 2000-01-31
JP2718637B2 (ja) 1998-02-25
RO114132B1 (ro) 1999-01-29
CN1108658A (zh) 1995-09-20
RU94036761A (ru) 1996-09-10
CZ283561B6 (cs) 1998-05-13
PT648771E (pt) 2001-09-28
GR3036068T3 (en) 2001-09-28
TW375615B (en) 1999-12-01
IL111273A0 (en) 1994-12-29
CN1039011C (zh) 1998-07-08

Similar Documents

Publication Publication Date Title
DE69427332T2 (de) Galanthamin-Derivat, ein Verfahren zu seiner Herstellung und seine Verwendung als Medikament
DE69429708D1 (de) Galanthamin Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69429570D1 (de) Galanthamin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
DE69331652D1 (de) Azetidinonverbindung und Verfahren zu ihrer Herstellung
DE3864707D1 (de) Benzoxazin-derivate und verfahren zu ihrer herstellung.
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
ATE135694T1 (de) Alkylthiopoly(ethylimidazolium)verbindungen, verfahren zur herstellung und deren verwendung als biozidemittel
EP0555479A4 (de)
ATE146476T1 (de) Cephalosporinverbindungen und verfahren zu ihrer herstellung
DE59905700D1 (de) N-phenylacetoacetamide und Verfahren zu ihrer Herstellung
ATE165596T1 (de) Verfahren zur herstellung von insektiziden, acariziden und molluskiziden 2-halo-pyrrol-3- carbonitrilen
DE3884518T2 (de) Naphthothiazepin-Derivate und Verfahren zu ihrer Herstellung.
DE69311999D1 (de) Verfahren zur Herstellung von Amino-Thiadiazolylacetylhaliden
ATE67194T1 (de) Thiadiazolylacetamid-derivate, verfahren zu ihrer herstellung und ihre verwendung.
ATE139767T1 (de) Verfahren zur herstellung 5-pyrazolomerkaptan- derivate und dessen zwischenprodukte
DE50000575D1 (de) Verfahren zur Herstellung von Folsäure
DE69419083D1 (de) Salmycine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition